Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy

Journal of the American Society of Nephrology

Volumn 8, Issue 9, 1997, Pages 1483-1490

  O'Brien, Sean ^a   Bernert, Richard A ^a   Logan, Joy L ^b   Lien, Yeong Hau H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AZATHIOPRINE; CYCLOSPORIN A; IMMUNOGLOBULIN; PREDNISONE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030777477     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Crawford DH, Thomas JA, Janossy G, Sweny P, Fernando ON, Moorhead JF, Thompson, JH: Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft [Letter]. Lancet 1: 1355-1356, 1980
2. Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL, Saemundsen AK, Klein G, Simmons RL, Najarian JS: Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 41: 4253-4261, 1981
3. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Balfour HH, Simmons RL, Najarian JS: Acyclovir therapy of Epstein-Barr virus-induced posttransplant lymphoproliferative disease. Transplant Proc 17: 89-92, 1985
4. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1: 583-587, 1984
5. Penn I: Cancer complicating organ transplantation. N Engl J Med 323: 1767-1769, 1990
6. Cohen JI: Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 70: 137-160, 1991
7. Seiden MV, Sklar J: Molecular genetic analysis of post transplant lymphoproliferative disorders. Hematol Oncol Clin N Am 17: 447-463, 1993
8. Swinnen LJ, Fisher RI: OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: A possible cause of lymphoproliferative disorders associated with transplantation. Curr Opin Nephrol Hypertens 2: 670-678, 1993
9. Mathur A, Kamat DM, Filipovich AH, Steinbuch M, Shapiro RS: Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders. Transplantation 57: 1042-1045, 1994
10. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Sakamoto K, Purtilo DT, Balfour HH Jr, Simmons RL, Najarian JS: Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 306: 913-918, 1982
11. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipient. N Engl J Med 323: 1723-1728, 1990
12. Batiuk TD, Barry JM, Bennett WM, Meyer MM, Tolzman D, Norman DJ: Incidence and type of cancer following the use of OKT3: A single center experience with 557 organ transplants. Transplant Proc 25: 1391, 1993
13. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J: The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133: 173-192, 1988
14. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, Lennette ET, Martinez OM, Krams SM, Berquist WE, So SK, Esquivel CO: An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 59: 524-529, 1995
15. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA: Posttransplant lymphoproliferative disorder in renal allograft recipients: Clinical experience and risk factor analysis in a single center. Transplantation 56: 88-96, 1993
16. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CG: Pretransplantation seronegative Epstein-Burr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations, J Heart Lung Transplant 14: 214-221, 1995
17. Haque T, Thomas JA, Falk KI, Parratt R, Hunt BJ, Yacoub M, Crawford DH: Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients, J Gen Virol 77: 1169-1172, 1996
18. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I: Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 103: 748-755, 1995
19. Penn I: Tumors after renal and cardiac transplantation. Hematol Oncol Clin N Am 7: 431-445, 1993
20. Lien YH, Schroter G, Weil R III, Robinson WA: Complete remission and possible immune-tolerance after multi-drug combination chemotherapy for cyclosporine-related lymphoma in renal transplant recipient presenting with acute pancreatitis. Transplantation 52: 739-742, 1991
21. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI: Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86: 3333-3340, 1995
22. Garrett TJ, Chadburn A, Barr ML, Drusin RE, Chen JM, Schulman LL, Smith CR, Reison DS, Rose EA, Michler RE: Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer (Phila) 72: 2782-2785, 1993
23. Trigg ME, Finlay JL, Sondel PM: Prophylactic acyclovir in patients receiving bone marrow transplants [Letter]. N Engl J Med 312: 1708, 1985
24. Leblond V, Sutton L, Dorent R, Davi F, Bitker MO, Gabarre J, Charlotte F, Ghoussoub JJ, Fourcade C, Fische A: Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 13: 961-968, 1995
25. Urabe A: Interferons for the treatment of hematological malignancies. Oncology 51: 137-141, 1994
26. Mandelli F, Arcese W, Avvisati G: The interferons in haematological malignancies. Bailliere's Clin Haematol 7: 91-113, 1994
27. Shapiro RS, Chauvenet A, McGuire W, Pearson A, McGlave P: Treatment of B cell lymphoproliferative disorders with interferon alpha and intravenous gamma globulin [Letter]. N Engl J Med 318: 1334, 1988
28. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B: Epstein-Barr virus-associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 71: 1234-1243, 1988
29. Kane RE, Bunchman TE, Vogler C, Brems JJ: Treatment of a B-ceil lymphoproliferative disorder in a liver transplant patient with interferon alfa and gamma globulin: A case report Clin Transplant 6: 154-158, 1992
30. Morrison VA, Dunn DL, Manievel JC, Gajl-Peczalska KJ, Peterson BA: Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 97: 14-24, 1994
31. Berg LC, Copenhaver CM, Morrison VA, Gruber SA, Dunn DL, Gajl-Peczalska K, Strickler JG: B-cell lymphoproliferative disorders in solid-organ transplant patients: Detection of Epstein-Barr virus by in situ hybridization. Hum Pathol 23: 159-164, 1992
32. Ippoliti G, Martinelli L, Lorenzutti F, Incardona S, Negri M, Balduzzi P, Rovati B, Ascari E, Vigano M: Posttransplant lymphoproliferative disease after heart transplantation on Sandimmune therapy: Treatment with role interferon alfa-2b and intravenous immunoglobulin. Transplant Proc 26 2660-2661, 1994
33. Faro A, Kurland G, Michaels MG, Dickman PS, Greally PG, Spichty KJ, Noyes BB, Boas SR, Fricker FJ, Armitage JM, Zeevi A: Interferon-alfa affects the immune response in post-transplant Lymphoproliferative disorder. Am J Respir Crit Care Med 153: 1442-1447, 1996
34. Garner JG, Hirsch MS, Schooley RT: Prevention of Epstein-Barr virus-induced B cell outgrowth by interferon-alpha. Infect Immun 43: 920-924, 1984
35. Cheeseman SH, Henle W, Rubin RN, Tolkoff-Rubin NE, Cosimi B, Cantell K, Winkle S, Herrin JT, Black PH, Russell PS, Hirsch MS: Epstein-Barr virus infection in renal transplant recipients: Effects of antithymocyte globulin and interferon. Ann Intern Med 93: 39-42, 1980